{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:50:14Z","timestamp":1788814214708,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijid.2026.108373","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:10:36Z","timestamp":1767946236000},"page":"108373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The cost-effectiveness of increasing hepatitis Delta testing for individuals co-infected with HBV and HIV in the Netherlands"],"prefix":"10.1016","volume":"164","author":[{"given":"Shyevon","family":"Marchena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehlika","family":"Toy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijid.2026.108373_bib0001","first-page":"651","article-title":"Hepatitis delta virus","volume":"11","author":"Hughes","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2026.108373_bib0002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ijid.2026.108373_bib0003","first-page":"857","article-title":"Hepatitis delta\u2013associated mortality in HIV\/HBV-coinfected patients","volume":"31","author":"B\u00e9guelin","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ijid.2026.108373_bib0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jmii.2013.08.001","article-title":"Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan","volume":"48","author":"Lee","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.ijid.2026.108373_bib0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108373_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104870","article-title":"Prevalence of hepatitis D virus among chronic hepatitis B carriers in a large tertiary centre in the Netherlands","volume":"141","author":"Beudeker","year":"2021","journal-title":"J Clin Virol"},{"issue":"7","key":"10.1016\/j.ijid.2026.108373_bib0007","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.7.2400344","article-title":"Low coverage of hepatitis D virus testing in individuals with HBV and HIV in the Netherlands, 2000\u20132022","volume":"29","author":"Boyd","year":"2024","journal-title":"Eurosurveillance"},{"issue":"2","key":"10.1016\/j.ijid.2026.108373_bib0008","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108373_bib0009","unstructured":"European Medicines Agency (EMA). (2022). Hepcludex (bulevirtide) \u2013 EPAR: product information. [accessed 15 June 2025]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"key":"10.1016\/j.ijid.2026.108373_bib0010","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"issue":"4","key":"10.1016\/j.ijid.2026.108373_bib0011","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1093\/cid\/ciaf181","article-title":"Cost-Effectiveness of One-time universal testing for hepatitis D among adults with chronic hepatitis B in the United States","volume":"81","author":"Toy","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108373_bib0012","unstructured":"Zorginstituut Nederland (ZiN). (2024). Guideline for economic evaluations in healthcare. [accessed 12 June 2025]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2024\/04\/01\/guideline-for-economic-evaluations-in-healthcare."},{"key":"10.1016\/j.ijid.2026.108373_bib0013","first-page":"1","article-title":"Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort","volume":"6","author":"de L\u00e9dinghen","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ijid.2026.108373_bib0014","unstructured":"Medicijnkosten.nl. (n.d.). Hepcludex injectiepoeder flacon 2mg. [accessed 21 May 2025]. https:\/\/www.medicijnkosten.nl\/medicijn?artikel=hepcludex\u00b1injectiepoeder\u00b1flacon\u00b12mg&id=5f20a7c04f86053a878976fbf4083177."},{"key":"10.1016\/j.ijid.2026.108373_bib0015","unstructured":"Sanquin. (n.d.). Anti-HDV super co-infectie met hepatitis delta virus \u2013 Diagnostische testen. [accessed 5 June 2025]. https:\/\/www.sanquin.org\/nl\/producten-en-diensten\/diagnostiek\/diagnostische-testen\/index\/name\/o300-anti-hdv-super-co-infectie-met-hepatitis-delta-virus."},{"key":"10.1016\/j.ijid.2026.108373_bib0016","unstructured":"GGD Amsterdam. (n.d.). Reisvaccinaties: kosten en vergoeding. [accessed 21 May 2025]. https:\/\/www.ggd.amsterdam.nl\/reisvaccinaties\/kosten-vergoeding\/."},{"key":"10.1016\/j.ijid.2026.108373_bib0017","unstructured":"RHMDC. (n.d.). Tarieven [Tariffs]. [accessed 18 June 2025] https:\/\/rhmdc.nl\/tarieven."},{"key":"10.1016\/j.ijid.2026.108373_bib0018","unstructured":"Medicijnkosten.nl. (2025). Pegasys 90 Injvlst 180 Mcg\/Ml Wwsp 0,5 ml. [accessed 18 June 2025] https:\/\/www.medicijnkosten.nl\/medicijn?artikel=PEGASYS\u00b1+90\u00b1INJVLST\u00b1180MCG%2FML\u00b1WWSP\u00b10%2C5ML&id=bc9375b1ab08639734e67bd2b01b98d1."},{"key":"10.1016\/j.ijid.2026.108373_bib0019","unstructured":"Medicijnkosten.nl. (2025). Tenofovirdisoproxil Glenmark tablet filmomh 245 mg. [accessed 18 June 2025] https:\/\/www.medicijnkosten.nl\/medicijn?artikel=TENOFOVIRDISOPROXIL\u00b1GLENMARK\u00b1TABLET\u00b1FILMOMH\u00b1245MG&id=c6da173e2b9f0734eb81ea5da72328e9."},{"issue":"3","key":"10.1016\/j.ijid.2026.108373_bib0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MEG.0000000000002905","article-title":"Increase in prevalence and costs of cirrhosis in the Netherlands: a nationwide hospital diagnosis data analysis","volume":"37","author":"de Wit","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108373_bib0021","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.dld.2023.01.143","article-title":"Bulevertide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: an exploratory analysis of a phase 3 trial at 48 weeks","volume":"55","author":"Buti","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.ijid.2026.108373_bib0022","first-page":"1524","article-title":"Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C","volume":"95","author":"Wong","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2026.108373_bib0023","unstructured":"Zorginstituut Nederland [ZiN] (2024). Kostenhandleiding voor economische evaluaties in de gezondheidszorg: methodologie en referentieprijzen. [accessed 15 June 2025]. https:\/\/www.zorginstituutnederland.nl\/site\/binaries\/site-content\/collections\/documents\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Verdiepingsmodule\u00b1Kostenhandleiding\u00b1%28versie\u00b12024%29.pdf."},{"key":"10.1016\/j.ijid.2026.108373_bib0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.ijid.2026.108373_bib0025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2009.10.039","article-title":"Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective","volume":"138","author":"Veldhuijzen","year":"2010","journal-title":"Gastroenterology"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:58:13Z","timestamp":1784548693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"alternative-id":["S1201971226000081"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108373","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of increasing hepatitis Delta testing for individuals co-infected with HBV and HIV in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108373"}}